Ani Pharmaceuticals (ANIP) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to -$262.6 million.
- Ani Pharmaceuticals' Enterprise Value fell 8111.39% to -$262.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$262.6 million, marking a year-over-year decrease of 8111.39%. This contributed to the annual value of -$144.9 million for FY2024, which is 3447.3% up from last year.
- Latest data reveals that Ani Pharmaceuticals reported Enterprise Value of -$262.6 million as of Q3 2025, which was down 8111.39% from -$217.8 million recorded in Q2 2025.
- In the past 5 years, Ani Pharmaceuticals' Enterprise Value registered a high of -$15.3 million during Q3 2021, and its lowest value of -$262.6 million during Q3 2025.
- In the last 5 years, Ani Pharmaceuticals' Enterprise Value had a median value of -$144.9 million in 2024 and averaged -$129.9 million.
- As far as peak fluctuations go, Ani Pharmaceuticals' Enterprise Value tumbled by 71838.04% in 2021, and later soared by 4944.59% in 2022.
- Quarter analysis of 5 years shows Ani Pharmaceuticals' Enterprise Value stood at -$105.3 million in 2021, then skyrocketed by 49.45% to -$53.2 million in 2022, then tumbled by 315.38% to -$221.1 million in 2023, then soared by 34.47% to -$144.9 million in 2024, then crashed by 81.27% to -$262.6 million in 2025.
- Its Enterprise Value stands at -$262.6 million for Q3 2025, versus -$217.8 million for Q2 2025 and -$149.8 million for Q1 2025.